BIOLOGICAL MARKERS FOR IDENTIFYING IBRUTINIB RESISTANCE IN PATIENTS HAVING MANTLE CELL LYMPHOMA AND METHODS OF USING THE SAME

By May 12, 2016May 4th, 2021Publications

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell lymphoma.